Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylstilbestrol Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.55 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylstilbestrol Diphosphate SCHEMBL9370 | 1.00 | BLM (1.00) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL2496868 | 0.98 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL809597 | 0.98 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL3664191 | 0.96 | BLM (0.93) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707840 | 0.93 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707841 | 0.93 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL7617243 | 0.93 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL14608595 | 0.90 | BLM (0.81) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL5488347 | 0.86 | BLM (0.74) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL8937910 | 0.85 | BLM (0.72) | BLMNR1I2SMN1; SMN2ESR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3528799-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | Pellficure Pharmaceuticals, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| WO-2018195202-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | PELLFICURE PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2018080933-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-1214055-A2 | PHARMACEUTICAL GEL CONTAINING ACTIVE SUBSTANCES | HEXAL AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2002045700-A2 | ABSORBING AGENTS AND COVER LAYER WHICH IS IMPERMEABLE TO ACTIVE SUBSTANCES AND WHICH CONTAINS CHANNEL-FORMERS OR REMOVABLE PROTECTIVE LAYER OF A TRANSDERMAL THERAPEUTIC SYSTEM | HEXAL AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-1185246-A1 | PHARMACEUTICAL COMPOSITION FOR INTRANASAL USE OF ACTIVE SUBSTANCES THAT ARE INSOLUBLE AND/OR HARDLY SOLUBLE IN WATER | Klöcker, Norbert, Dr.med. (DE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001097832-A1 | PHARMACEUTICAL PREPARATIONS CONTAINING CYCLOSPORINES AND NEUTRAL OILS | AUDIT INSTITUTE FOR MEDICAL SERVICES AND QUALITY ASSURANCE GMBH (DE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001097774-A2 | NOVEL PHARMACEUTICAL COMPOSITION FOR THE TOPICAL APPLICATION OF WATER-INSOLUBLE AND/OR HARDLY WATER-SOLUBLE ACTIVE AGENTS | AUDIT INSTITUTE FOR MEDICAL SERVICES AND QUALITY ASSURANCE GMBH (DE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001021153-A2 | PHARMACEUTICAL GEL CONTAINING ACTIVE SUBSTANCES | HEXAL AG (DE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000074651-A1 | PHARMACEUTICAL COMPOSITION FOR INTRANASAL USE OF ACTIVE SUBSTANCES THAT ARE INSOLUBLE AND/OR HARDLY SOLUBLE IN WATER | HEXAL AG (DE) | 2000-12-14 | — | — | WO | disclosed |
| EP-0689430-B1 | SUPERPARAMAGNETIC PARTICLES, PROCESS FOR PRODUCING THE SAME AND THEIR USE | SILICA GEL GMBH (DE) | 1997-08-13 | — | — | EP | disclosed |
| EP-0689430-A1 | SUPERPARAMAGNETIC PARTICLES, PROCESS FOR PRODUCING THE SAME AND THEIR USE | SILICA GEL GMBH (DE) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021240-A2 | SUPERPARAMAGNETIC PARTICLES, PROCESS FOR PRODUCING THE SAME AND THEIR USE | SILICA GEL GES.M.B.H (DE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885BLM 564/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885BLM 564/4885 |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | DHPS, SRD5A2, SRD5A1 | ESR1 2341/4885ESR2 2002/4885BLM 3846/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885BLM 564/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885BLM 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.